Alembic Pharmaceuticals posted double-digit revenue growth in Q3, with margins steady, though a one-time labour code provision weighed on net profit despite strong global execution.
Alembic Pharmaceuticals posted double-digit revenue growth in Q3, with margins steady, though a one-time labour code provision weighed on net profit despite strong global execution.